Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Fluridil, a non-steroidal anti-androgen approved for alopecia in parts of Europe, is noted for its low side effects but is not commonly discussed. The user is inquiring if anyone prefers it over other anti-androgens like Spiro or RU58841.

Folligenz liposomal minoxidil sulfate is being discussed for its effectiveness and cost, with users comparing it to regular minoxidil and tretinoin. One user found no difference with the 10% version and noted that a lower tretinoin percentage reduced side effects like skin peeling.

Applying minoxidil in the morning and topical finasteride at night. Mixing finasteride with liquid minoxidil is planned after finishing foam bottles.

New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

Lighting can significantly affect the perception of hair progress in photos. The user has been using dutasteride and oral minoxidil for hair loss, noting improvements after switching from finasteride.

A user, 35M, has been using oral finasteride for 5 years and 5% minoxidil for 3 years, which stopped hair loss but didn't promote regrowth. After starting RU58841 5 months ago, they noticed long, translucent hairs and are asking if these hairs will darken and how to encourage this.

The user observed some regrowth and longer baby hairs after one month of using finasteride, despite experiencing increased shedding. They noted no side effects except for clear semen.

RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.

AltruisticBro's experience with Fluridil (Eucapil) as a hair loss treatment, and the current blood work results associated with it. They are not willing to take finasteride due to potential permanent side effects.

Pyrilutamide's systemic degradation is unclear, unlike fluridil, which becomes inactive in the body. The discussion focuses on whether pyrilutamide shares this property.

PG solvent is considered superior to K&B solvent for RU58841 and Pyralutamide due to cost and effectiveness. The user questions why they should use K&B when PG offers more benefits.

The user uses Toppik hair fibers to thicken their hairline and has switched from finasteride to dutasteride and oral minoxidil, noticing more hair thickening. Most responses indicate the hair fibers are not noticeable, and many suggest the user doesn't need them as their hair looks natural and good for their age.

A 28-year-old male using only oral finasteride 1mg since May 15, 2024, reports no side effects and significant hair improvement. He plans to continue finasteride for three more months and is considering adding D3+K2 drops, zinc, folate, and magnesium glycinate.

NMN is considered safe to use with dutasteride, and it may help reduce grey hairs. Combining NMN with creatine, whey protein, fish oil, and dutasteride is not seen as excessive.

Hair loss treatments, including Alfatradiol, Minoxidil, Finasteride, and RU58841. It discusses the efficacy of these treatments for hair growth and regrowth.

Mixing minoxidil and alfatradiol in one bottle may affect their effectiveness due to potential stability issues. It's recommended to apply them separately for full benefits.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

Minoxidil, dutasteride, and copper peptides are used in a tattooing method for hair regrowth, with some users noting better results compared to oral treatments. Copper peptides are considered to have minimal impact, but the method may reduce side effects.

The conversation discusses progress with a hair loss treatment regimen that includes once daily topical Finasteride, Pyrilutamide, and WAY-316606. Specific treatments for hair loss are being shared and discussed.

Researching the release of phase 2 trials for pyrilutamide, a potential hair loss treatment, and discussing other treatments such as Minoxidil, Finasteride, and RU58841.